Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue 2, 2002, Pages 178-182

  De Truchis, Pierre ^a,i   Force, Gilles ^b   Welker, Yves ^c   Mechali, Denis ^d   Pulik, Marc ^e   Chemlal, Kadoudja ^f   Rouveix, Elisabeth ^g   Devidas, Alain ^j   Praindhui, Danielle ^h   Mamet, Jean Philippe ^h  

^a Hôpital Garches   (France)

^b Hôpital Levallois Perret   (France)

^c Hôpital Saint Germain   (France)

^d Hôpital Saint Denis   (France)

^e CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^f Hôpital Nanterre   (France)

^g Hôpital Boulogne   (France)

^h GLAXOSMITHKLINE   (France)

ⁱ RAYMOND POINCARÉ HOSPITAL   (France)

^j NONE

more..

Author keywords

Clinical trial; Highly active antiretroviral therapy; Protease inhibitor sparing

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INSOMNIA; LIPODYSTROPHY; LYMPHOCYTE COUNT; MALAISE; MALE; MULTICENTER STUDY; MYOSITIS; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SLEEP DISORDER; STATISTICAL ANALYSIS; STOMACH PAIN; VERTIGO; VIREMIA; VIRUS LOAD; VOMITING;

EID: 0036798488     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200210010-00008     Document Type: Article

References (13)

1. Moyle GJ. Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection Curr Opin Infect Dis 2000;13:19-25.
2. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-73.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleosides analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
4. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial JAMA 2001;285:1155-63.
5. Carpenter C, Cooper D, Fischl M, et al. Antiretroviral therapy in adults: updated recommendations of the international AIDS Society-USA Panel. JAMA 2000;283:381-90.
6. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-73.
7. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy. Arch Intern Med 2000;160:2050-6.
8. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1- protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998,351:1881-3.
9. Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med 1998;13:586-93.
10. Yerly S, Perneger T, Vora S, et al. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 2000;14:2805-12.
11. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15:1369-77.
12. Raboud J, Montaner J, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS 1998;12:1619.
13. Moyle G, Pozniak A, Opravil M, et al. The SPICE study: 48-week activity of combination of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. J Acquir Immune Defic Syndr 2000;23:128-37.